Early life respiratory syncytial virus disease-a preventable burden
- PMID: 38701821
- DOI: 10.1016/S1473-3099(24)00261-5
Early life respiratory syncytial virus disease-a preventable burden
Conflict of interest statement
CC reports grants from the US Centers for Disease Control and Prevention, PATH, the Bill & Melinda Gates Foundation, the South African Medical Research Council, Wellcome Trust, and Sanofi Pasteur. HJZ reports grants from the Gates Foundation, the National Institutes of Health, the South African Medical Research Council, Pfizer, AstraZeneca, and Merck Sharp & Dohme for RSV-related studies and serves on data safety monitoring boards for Moderna and Merck Sharp & Dohme and advisory boards for Pfizer.
Comment on
-
Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.Lancet Infect Dis. 2024 Aug;24(8):817-828. doi: 10.1016/S1473-3099(24)00215-9. Epub 2024 Apr 30. Lancet Infect Dis. 2024. PMID: 38701823
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
